InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) Corrects After Serious Spike

[[tagnumber 0]][[tagnumber 1]]It is no doubt that InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) has had a great run in the second half of October, going from around $0.50 per share to the footsteps of the $1 per share mark, while the good news kept on coming.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The company has already crossed the $1 mark and is moving forward while recently we got to see their financials for the third quarter. The report filed on November 5 shows that NVIV’s numbers of prime interest are still decent considering the stock is listed on the OTC markets.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 9]] [[tagnumber 10]]cash: $17.63 million[[tagnumber 11]] [[tagnumber 10]]current assets: $18.34 million[[tagnumber 11]] [[tagnumber 10]]total assets: $20.28 million[[tagnumber 11]] [[tagnumber 10]]current liabilities: $4.81 million[[tagnumber 11]] [[tagnumber 10]]total liabilities: $6.73 million[[tagnumber 11]] [[tagnumber 10]]revenues: $0[[tagnumber 11]] [[tagnumber 10]]net loss: $1.21 million[[tagnumber 11]] [[tagnumber 24]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The net loss is significantly lower due to derivative gains and we see that NVIV have lowered their current liabilities by about $3 million compared to Q2. The sound state of the company, however, didn’t impress investors that much and NVIV kept hovering around the $1 mark.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The more recent news, on the other hand sparked some serious investor interest. Several news channels reported that the operation of 25 year old Jordan Fallis, the first patient to ever receive the treatment, has went well and Mr. Fallis himself stated that he’s getting feeling back in the lower part of his body.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This led to a serious 37.50% jump in Wednesday’s session and a massive daily dollar volume of $6.52 million, the biggest one since May. Unfortunately, the hype didn’t last long and NVIV closed 4.90% lower yesterday, at $1.36 per share, recording $5.41 million in trade value.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Let’s not forget that NVIV is still at the early stages of the testing of its treatment and the company is taking slow steps to possible future success. That being said, we consider that doing your due diligence and weighing out the risks that come with any investment is crucial.[[tagnumber 2]]